

Maria Bjurberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/150796/publications.pdf>

Version: 2024-02-01

22
papers

300
citations

933447

10
h-index

888059

17
g-index

23
all docs

23
docs citations

23
times ranked

468
citing authors

#	ARTICLE	IF	CITATIONS
1	Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer – a Swedish Gynecologic Cancer Group (SweGCG) study. <i>Acta Oncologica</i> , 2019, 58, 1628-1633.	1.8	55
2	Data quality in the Swedish Quality Register of Gynecologic Cancer – a Swedish Gynecologic Cancer Group (SweGCG) study. <i>Acta Oncologica</i> , 2018, 57, 346-353.	1.8	41
3	Prediction of Patient Outcome With 2-Deoxy-2-[¹⁸ F]fluoro-D-Glucose-Positron Emission Tomography Early During Radiotherapy for Locally Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1600-1605.	2.5	26
4	Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). <i>Gynecologic Oncology</i> , 2017, 144, 167-173.	1.4	23
5	Early Changes in 2-Deoxy-2-[¹⁸ F]Fluoro-D-Glucose Metabolism in Squamous-Cell Carcinoma During Chemotherapy <i>in Vivo</i> and <i>In Vitro</i> . <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 327-332.	1.0	21
6	FDG-PET in cervical cancer: staging, re-staging and follow-up. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 1385-1391.	2.8	17
7	Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease – a Swedish Gynecologic Cancer Group (SweGCG) study. <i>Acta Oncologica</i> , 2018, 57, 331-337.	1.8	17
8	Preoperative and intraoperative assessment of myometrial invasion in endometrial cancer – A Swedish Gynecologic Cancer Group (SweGCG) study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1526-1533.	2.8	16
9	Auto-segmentations by convolutional neural network in cervical and anorectal cancer with clinical structure sets as the ground truth. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 37-45.	1.7	13
10	Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study. <i>Gynecologic Oncology</i> , 2019, 155, 229-236.	1.4	12
11	FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre.. <i>Acta Oncologica</i> , 2006, 45, 743-749.	1.8	11
12	Primary treatment and relative survival by stage and age in vulvar squamous cell carcinoma: A population-based SweGCG study. <i>Gynecologic Oncology</i> , 2020, 159, 663-671.	1.4	10
13	ATL. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1642-1646.	2.5	9
14	Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6057-6057.	1.6	7
15	Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study. <i>Gynecologic Oncology</i> , 2021, 161, 244-250.	1.4	6
16	Cell proliferation, measured as flow cytometric S-phase fraction, is a strong prognostic indicator in FIGO stage I endometrioid endometrial carcinoma: a population-based study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2015, 94, 1064-1073.	2.8	5
17	Long-term incidence of endometrial cancer after endometrial resection and ablation: A population based Swedish gynecologic cancer group (SweGCG) study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 0, , .	2.8	4
18	Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5504-5504.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Survival in endometrial cancer in relation to minimally invasive surgery or open surgery â€” a Swedish Gynecologic Cancer Group (SweGCG) study. BMC Cancer, 2021, 21, 658.	2.6	2
20	Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study. Gynecologic Oncology, 2018, 148, 363-367.	1.4	0
21	A population-based study of pelvic serous carcinoma in Sweden: Primary site, FIGO stage and survival.. Journal of Clinical Oncology, 2015, 33, e16533-e16533.	1.6	0
22	The wait time to primary surgery in endometrial cancer â€” impact on survival and predictive factors: a population-based SweGCG study. Acta OncolÃ³gica, 2022, 61, 30-37.	1.8	0